Ovelle's co-founders exemplify a common success pattern in biotech: one partner with profound scientific knowledge (Merrick) and another with extensive business experience (Travis). This combination covers critical aspects from research to capital raising and team building, as it's rare to find both skill sets in one person.

Contrary to conventional wisdom, deep sector expertise can be a liability in venture capital. VC firm Felicis found that none of its 53 unicorn investments were led by an expert in that specific sector. Experts can be anchored to orthodox thinking, while generalists are better able to recognize and back disruptive, first-principles approaches.

A key skill in building a deep tech team is identifying individuals who can bridge the gap between complex science and business reality. These "translators" can articulate highly technical concepts in plain English, clarifying clinical relevance and commercial viability for decision-makers.

The life sciences investor base is highly technical, demanding concrete data and a clear path to profitability. This rigor acts as a natural barrier to the kind of narrative-driven, AI-fueled hype seen in other sectors, delaying froth until fundamental catalysts are proven.

Overly technical experts can easily dissuade investors from promising companies. A generalist's perspective, applying insights from other industries and focusing on a longer time horizon, can reveal value that specialists, mired in detail and conventional wisdom, might overlook.

A critical step for technical founders is honestly assessing their non-scientific weaknesses. Professor Waranyoo Phoolcharoen knew she couldn't be both CTO and CEO, so she deliberately sought a co-founder with strong business, finance, and marketing skills to complement her technical expertise.

A biotech investor's role mirrors that of a record producer by identifying brilliant talent (scientists) who may lack commercial experience. The investor provides the capital, structure, and guidance needed to translate raw scientific innovation into a commercially successful product.

Forbion's success stems from its diverse team, which goes beyond typical MDs and PhDs. By integrating partners with backgrounds in banking, physics, and finance, the firm evaluates deals holistically—assessing not just the science but also deal structures, risk mitigation, and exit strategies like M&A and IPOs.

Luba Greenwood argues that unlike in tech, many biotech CEOs lack P&L experience. In today's cash-constrained market, CEOs need to be able to build financial models and understand finance deeply to be effective, a skill she personally developed after transitioning from law and science.